US FDA expands Abecma's indication, approving CAR T cell therapy for triple-class exposed relapsed or refractory multiple myeloma.
The US FDA expands Abecma's indication, approving Bristol Myers Squibb and 2seventy bio's CAR T cell therapy for triple-class exposed relapsed or refractory multiple myeloma after two prior lines of therapy. The approval is based on the KarMMa-3 trial and Abecma is administered as a one-time infusion. It is now approved in the US, Japan, Switzerland, and the EU.
April 05, 2024
6 Articles